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Asymptomatic hyperuricemia has been detected in association with a number of situations associated with chronic renal disease, including 
insulin resistance, hypertension, cerebrovascular and 
heart disease. Experimental investigations indicate that 
serum uric acid may directly and indirectly promote 
kidney damage by various pathogenetic mechanisms 
both at cellular and tissue level (1,2). Recently in a cross-
sectional setting, a sample containing 643 (302 prediabetic 
subjects and 341 normal) of the first-degree relatives 
of diabetic patients, the authors, found prediabetic 
individuals had significantly higher uric acid than normal 
persons (3). They also found, patients in the higher uric 
acid quartiles exhibited higher levels of body mass index, 
SBP, FBG and triglycerides. The higher quartiles of uric 
acid tended to be associated with higher BMI and higher 
total cholesterol in females prediabetic individuals. They, 
additionally detected, uric acid was positively associated 
with glucose tolerance categories. This association 
remained statistically significant after adjusting the effects 
of age and BMI. Furthermore, the association between 
glucose tolerance categories and uric acid were positively 
significant in both genders (3). They concluded that, high 
uric acid level was associated with some cardiometabolic 
risk factors in prediabetic individuals compared with 
normal person and also serum uric acid level was also 
a significant predictor for prediabetes situation (3). In 
recent years, much attention has been directed toward the 
impact of uric acid on metabolic syndrome and its role on 
the aggravation of kidney or hypertension. In fact, besides 
of various well-known risk factors such as high blood 
pressure and diabetes, various “non-traditional” risk 
factors may related to the higher risk of kidney damage 
compared to the general population (1-4). Recently in 
an investigation on 60 type II diabetics without a history 
of gout, we observed a significant positive correlation 
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medical education
In recent years much attention has been directed 
toward the impact of uric acid on metabolic syndrome 
and its role on the aggravation of kidney function or 
hypertension. It seems, in addition to the some well-
known risk factors such as high blood pressure and 
diabetes, various “non-traditional” risk factors may 
related to the higher risk of kidney damage compared 
to the general population.
between body mass index and serum uric acid level. After 
adjustment for weight, a significant positive association 
of serum uric acid with level of proteinuria was detected 
too (5). Additionally, the association of serum uric acid 
with level of blood pressure was significantly positive 
(6). Accordingly, Jalalzadeh et al., conducted a single-
blind, randomized cross-over clinical study consisting 
55 patients on regular hemodialysis with serum uric acid 
level >6.5 (men) and >5.5 mg/dl (women) (7-10). They 
noticed to the reduction of blood pressure following 
treatment by in their study patients (11). Recent studies 
shown that treatment of hyperuricemia is associated 
with increases of plasma 1,25(OH)2D levels, proposing 
that hyperuricemia may have a suppressive influence 
on 1-α hydroxylase activity (7). Hence, it is likely that, 
high plasma uric acid levels, reduce plasma 1,25(OH)2D 
levels by suppressing 1-α hydroxylase and, while low 
1,25(OH)2D levels can stimulate parathyroid hormone. 
Thus, high uric acid levels may be associated with elevated 
PTH levels too (1-8). To attest this hypothesis, Chen et al, 
in an in-vivo investigation on Sprague Dawley rats, found 
uric acid suppresses, 1 alpha hydroxylase in vitro and in 
vivo (9). In fact, a reduction in 1,25(OH)2D secondary 
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to reduced 1-α hydroxylase enzyme activity contributes 
to the development of secondary hyperparathyroidism 
in patients with chronic kidney disease (8,9). Indeed, 
the direct relationship of hyperuricemia and vitamin D 
metabolism has two outcomes. Firstly it is well recognized 
that hyperuricemia by itself is an independent risk 
factor for renal injury in various nephropathies, like IgA 
nephropathy or diabetic nephropathy (8-10). Several 
studies, support the hypothesis that raised uric acid levels 
might have an injurious effect, resulting to inflammation, 
endothelial dysfunction and resultant vasculopathy (8-
12). Secondly, regardless of the deleterious effect role of 
hyperuricemia on high blood pressure and worsening of 
some type of nephropathies, its harmful effect of vitamin 
D production is of significant importance (8-12). Various 
studies had supports, vitamin D as a negative regulator 
of the circulating and local tissue renin-angiotensin 
system (RAS), while RAS has a critical implication in the 
physiology of volume homeostasis and sodium and. While 
excess activity of RAS is associated with hypertension, 
renal disease and diabetes (8-12).
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